On September 12, 2024 FibroBiologics, a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, reported the filing of a patent application with the United States Patent Office covering the use of fibroblast cell-based technology in generating three-dimensional hemopoietic organoids that can give rise to immune cells (Press release, FibroBiologics, SEP 12, 2024, View Source [SID1234656333]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The patent details methods of generating three-dimensional organoids capable of giving rise to hematopoietic cells, including precursors, and/or immune cells. This includes cells such as T cells, B cells, NK cells, macrophages, monocytes, neutrophils, platelets, red blood cells, myeloid-derived suppressor cells, mast cells, eosinophils, basophils, dendritic cells, and CAR-T cells.
"This method potentially offers a rapid, cost-effective, and scalable way to produce therapeutic hemopoietic organoids, which can be transplanted into a living organism to generate desired functional immune cells," commented Chief Scientific Officer of FibroBiologics, Hamid Khoja, Ph.D. "Additionally, the three-dimensional organoids can be ready for immediate transplantation into a subject within three days of culture or cryopreserved for later use."
"Our ongoing exploration of therapeutic applications using fibroblast cells continues to provide unique opportunities for our platform," commented Founder & CEO of FibroBiologics, Pete O’Heeron. "This patent, if issued, will allow us to pursue the development of a versatile, scalable solution for generating immune cells in vivo that could revolutionize regenerative medicine and cancer immunotherapy."